Evoke Pharma, Inc.

NasdaqCM:EVOK Stock Report

Market Cap: US$9.9m

Evoke Pharma Future Growth

Future criteria checks 5/6

Evoke Pharma is forecast to grow earnings and revenue by 124.7% and 59.5% per annum respectively while EPS is expected to grow by 114.6% per annum.

Key information

124.7%

Earnings growth rate

114.6%

EPS growth rate

Pharmaceuticals earnings growth19.8%
Revenue growth rate59.5%
Future return on equityn/a
Analyst coverage

Low

Last updated08 Nov 2024

Recent future growth updates

Recent updates

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Jan 22
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke to get US patent for nasal spray Gimoti

Sep 20

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Aug 10

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Jul 06

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Oct 22
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Jul 06
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Evoke Pharma announces positive findings from second GIMOTI market research study

Jun 15

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Jun 08

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Jun 02

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Mar 14
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Earnings and Revenue Growth Forecasts

NasdaqCM:EVOK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026329N/AN/A1
12/31/2025201N/AN/A1
12/31/202410-5N/AN/A1
9/30/20249-6-5-5N/A
6/30/20248-7-6-6N/A
3/31/20246-7-6-6N/A
12/31/20235-8-5-5N/A
9/30/20234-8-6-6N/A
6/30/20234-8-6-6N/A
3/31/20233-8-7-7N/A
12/31/20223-8-7-7N/A
9/30/20222-8-6-6N/A
6/30/20222-8-11-11N/A
3/31/20222-8-11-11N/A
12/31/20212-9-12-12N/A
9/30/20211-9-12-12N/A
6/30/20210-9-8-8N/A
3/31/20210-14-8-8N/A
12/31/20200-13-7-7N/A
9/30/2020N/A-12-6-6N/A
6/30/2020N/A-12-5-5N/A
3/31/2020N/A-7-5-5N/A
12/31/2019N/A-7-6-6N/A
9/30/2019N/A-7-6-6N/A
6/30/2019N/A-7-6-6N/A
3/31/2019N/A-8-6-6N/A
12/31/2018N/A-8-7-7N/A
9/30/2018N/A-6-8-8N/A
6/30/2018N/A-10N/A-10N/A
3/31/2018N/A-9N/A-10N/A
12/31/2017N/A-12N/A-9N/A
9/30/2017N/A-13N/A-7N/A
6/30/2017N/A-11N/A-8N/A
3/31/2017N/A-13N/A-8N/A
12/31/2016N/A-11N/A-9N/A
9/30/2016N/A-12N/A-10N/A
6/30/2016N/A-12N/A-10N/A
3/31/2016N/A-12N/A-10N/A
12/31/2015N/A-12N/A-10N/A
9/30/2015N/A-12N/A-11N/A
6/30/2015N/A-14N/A-12N/A
3/31/2015N/A-14N/A-12N/A
12/31/2014N/A-13N/A-12N/A
9/30/2014N/A-12N/A-11N/A
6/30/2014N/A-9N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVOK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: EVOK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EVOK is expected to become profitable in the next 3 years.

Revenue vs Market: EVOK's revenue (59.5% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: EVOK's revenue (59.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 14:35
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evoke Pharma, Inc. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Edward WooAscendiant Capital Markets LLC
Difei YangBrean Capital